Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Hepatitis A Seroprevalence Among Patients with Chronic Hepatitis B Infection: A Cross-Sectional Study in Iran During 2016-2017

Author(s): Seyed Ali Dehghan Manshadi, Neda Alijani, Mohammadreza Salehi, Omid Dadras, SeyedAhmad SeyedAlinaghi, Ailar Ahangari, Alireza Abdolahi, Hamidreza Davoudi and Ramazanali Alizade*

Volume 20, Issue 5, 2020

Page: [748 - 751] Pages: 4

DOI: 10.2174/1871526519666191009144848

Price: $65

Abstract

Introduction: The aim of this study was to determine the prevalence of exposure to hepatitis A by means of serologic markers in chronic hepatitis B patients, with the secondary aim of finding the best prevention method for hepatitis A infection in susceptible groups of our setting.

Methods: During the period between 2016 and 2017, we recruited 403 hepatitis B patients aged more than 14 years and regularly attending the infectious diseases clinic at a referral university hospital, Tehran, Iran. A blood sample was collected from all the patients and tested for hepatitis A IgG. The data was analyzed by SPSS v.19.

Results: Although none of the patients had previously received hepatitis A vaccine, the results for serologic level of hepatitis A IgG, demonstrated positive results in 379 (94%) cases. The mean age of patients with negative and positive IgG was 29.17 and 42.46 years, respectively; the difference was statistically significant (P≤0.001). The majority of seronegative patients were young adults aged < 25 years and 25 to 35 years (P <0.001).

Conclusion: Seroprevalence of hepatitis A in chronic HBV patients in Iran is high. As HBV infected patients younger than 35 years could be seronagative for HAV infection, evaluation of these patients for HAV infection and vaccination of seronegative patients would be a reasonable approach.

Keywords: Seroprevalence, chronic hepatitis B, hepatitis A IgG, Iran, HAV, asymptomatic disease.

[1]
Özden, H.T. Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey. Eur. J. Gastroenterol. Hepatol., 2016, 28(3), 333-337.
[http://dx.doi.org/10.1097/MEG.0000000000000547] [PMID: 26703930]
[2]
Bennett, J.; Dolin, R.; Blaser, M. Principles and Practice of Infectious Diseases, 8th ed; Elsevier: Canada, 2015.
[3]
Shapiro, C. Epidemiology of hepatitis A in the United States.Viral hepatitis and liver disease; Hollinger, F.; Lemon, S; Margolis, H., Ed.; Williams and Wilkins: Baltimore, 1991.
[4]
Kliegman, R. Nelson Textbook of Pediatrics, 20th ed; Elsevier: Canada, 2016.
[5]
Shoaei, P.; Najafi, S.; Zeid Abadi Nejad, L.; Ataei, B.; Yaran, M.; Nokhodian, Z. Seroprevalence of hepatitis A among individuals with chronic hepatitis B infection in Isfahan Province, Iran. Braz. J. Biol. Sci., 2015, 2, 17-21.
[6]
Keeffe, E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am. J. Gastroenterol., 1995, 90(2), 201-205.
[PMID: 7847285]
[7]
Vento, S.; Garofano, T.; Renzini, C.; Cainelli, F.; Casali, F.; Ghironzi, G.; Ferraro, T.; Concia, E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N. Engl. J. Med., 1998, 338(5), 286-290.
[http://dx.doi.org/10.1056/NEJM199801293380503] [PMID: 9445408]
[8]
Pramoolsinsap, C.; Poovorawan, Y.; Hirsch, P.; Busagorn, N.; Attamasirikul, K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann. Trop. Med. Parasitol., 1999, 93(7), 745-751.
[http://dx.doi.org/10.1080/00034983.1999.11813480] [PMID: 10715703]
[9]
Tsang, S.W.; Sung, J.J. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment. Pharmacol. Ther., 1999, 13(11), 1445-1449.
[http://dx.doi.org/10.1046/j.1365-2036.1999.00628.x] [PMID: 10571600]
[10]
Jefferies, M.; Rauff, B.; Rashid, H.; Lam, T.; Rafiq, S. Update on global epidemiology of viral hepatitis and preventive strategies. World J. Clin. Cases, 2018, 6(13), 589-599.
[http://dx.doi.org/10.12998/wjcc.v6.i13.589] [PMID: 30430114]
[11]
Franco, E.; Meleleo, C.; Serino, L.; Sorbara, D.; Zaratti, L.; Hepatitis, A.; Hepatitis, A. Epidemiology and prevention in developing countries. World J. Hepatol., 2012, 4(3), 68-73.
[http://dx.doi.org/10.4254/wjh.v4.i3.68] [PMID: 22489258]
[12]
SeyedAlinaghi S.A.; Kheirandish, P.; Karami, N.; Salem, S.; Shirzad, H.; Jahani, M.R.; SeyedAhmadian, M.R.; Valiollahi, P.; Hosseini, M.; Mohraz, M.; McFarland, W. High prevalence of chronic hepatitis B infection among injection drug users in Iran: the need to increase vaccination of adults at risk. Acta Med. Iran., 2010, 48(1), 58-60.
[PMID: 21137671]
[13]
Haeri Mazanderani, A.; Motaze, N.V.; McCarthy, K.; Suchard, M.; du Plessis, N.M. Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015. PLoS One, 2019, 14(6)e0216033
[http://dx.doi.org/10.1371/journal.pone.0216033] [PMID: 31242191]
[14]
SeyedAlinaghi S.; Jam, S.; Mehrkhani, F.; Fattahi, F.; Sabzvari, D.; Kourorian, Z.; Jabbari, H.; Mohraz, M. Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta Med. Iran., 2011, 49(4), 252-7.
[15]
Izadi, M.; Esfahani, A.A.; Hassannia, H.; Jonaidi Jafari, N.; Rahmati Najarkolaei, F.; Rezaee-Zavareh, M.S. Seroprevalence of hepatitis A virus among Iranian soldiers. Gastroenterol. Hepatol. Bed Bench, 2016, 9(2), 100-104.
[PMID: 27099669]
[16]
Karaman, S.; Karaman, K.; Kızılyıldız, B.S.; Ceylan, N.; Kaba, S.; Parlak, M.; Beger, B.; Ceylan, A. Seroprevalence of hepatitis a and associated factors among 1-15 year old children in Eastern Turkey. Int. J. Clin. Exp. Med., 2015, 8(10), 19394-19399.
[PMID: 26770581]

Rights & Permissions Print Cite
Article Metrics
29
© 2024 Bentham Science Publishers | Privacy Policy